United States was the largest of Phibro Animal Health Corp’s 4 reported lines in fiscal 2026, at $877.13M — 58% of $1.52B.
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $578.77M | $584.76M | $739.92M | $877.13M | |||||||||||
| Revenuefromcontractwithcustomerincludingassessedtax | — | — | — | — | |||||||||||
| Revenues | — | — | — | — | |||||||||||
| Latin America & Canada | $219.85M | $247.71M | $298.65M | $340.67M | |||||||||||
| Europe, Middle East & Africa | $117.82M | $121.98M | $160.23M | $187.94M | |||||||||||
| Asia Pacific | $61.46M | $63.23M | $97.42M | $112.36M | |||||||||||
| Total | $977.89M | $1.02B | $1.30B | $1.52B |
In fiscal 2026, which ended June 30, 2026, the 4 regions Phibro Animal Health Corp reported in this breakdown added up to $1.52B. That was up 17.1% from $1.30B in fiscal 2025. United States was the largest region, at $877.13M or 57.8% of the total, followed by Latin America & Canada ($340.67M, 22.4%) and Europe, Middle East & Africa ($187.94M, 12.4%). Together, the two largest regions made up 80.2% of this total.
Compared with fiscal 2025, United States grew the fastest, rising 18.5% to $877.13M. Every sizeable region reported in both years grew. Over fiscal 2023 to 2026, revenue across these regions went from $977.89M to $1.52B, a compound annual growth rate of 15.8%. United States' share of the total fell from 59.2% to 57.8% over the same years.
The table also keeps 2 regions that Phibro Animal Health Corp no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2012 to 2026, as reported in Phibro Animal Health Corp's annual filings.
Mfas & Other was the largest of Phibro Animal Health Corp’s 5 reported lines in fiscal 2026, at $810.73M — 53% of $1.52B.
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|
| Mfas & Other | $387.35M | $420.96M | $646.35M | $810.73M | ||
| Mineral Nutrition | $242.66M | $243.66M | $253.24M | $282.34M | ||
| Nutritional Specialties | $172.50M | $164.67M | $179.29M | $195.07M | ||
| Vaccines | $100.00M | $120.85M | $137.15M | $156.42M | ||
| Performance Products | $75.38M | $67.53M | $80.18M | $73.53M | ||
| Total | $977.89M | $1.02B | $1.30B | $1.52B |
In fiscal 2026, which ended June 30, 2026, the 5 revenue lines Phibro Animal Health Corp reported in this breakdown added up to $1.52B. That was up 17.1% from $1.30B in fiscal 2025. Mfas & Other was the largest revenue line, at $810.73M or 53.4% of the total, followed by Mineral Nutrition ($282.34M, 18.6%) and Nutritional Specialties ($195.07M, 12.8%). Together, the two largest revenue lines made up 72.0% of this total.
Compared with fiscal 2025, Mfas & Other grew the fastest, rising 25.4% to $810.73M. Performance Products fell the most, down 8.3% to $73.53M. Over fiscal 2023 to 2026, revenue across these revenue lines went from $977.89M to $1.52B, a compound annual growth rate of 15.8%. Mfas & Other's share of the total rose from 39.6% to 53.4% over the same years.
This breakdown covers every fiscal year from 2021 to 2026, as reported in Phibro Animal Health Corp's annual filings.
Animal Health was the largest of Phibro Animal Health Corp’s 3 reported lines in fiscal 2026, at $1.16B — 77% of $1.52B.
| Segment | FY 2012 | FY 2012 | FY 2012 | FY 2013 | FY 2013 | FY 2013 | FY 2013 | FY 2014 | FY 2014 | FY 2014 | FY 2014 | FY 2015 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Health | $659.85M | $706.48M | $962.80M | $1.16B | ||||||||||||||||||||
| Revenuefromcontractwithcustomerincludingassessedtax | — | — | — | — | ||||||||||||||||||||
| Revenues | — | — | — | — | ||||||||||||||||||||
| Mineral Nutrition | $242.66M | $243.66M | $253.24M | $282.34M | ||||||||||||||||||||
| Performance Products | $75.38M | $67.53M | $80.18M | $73.53M | ||||||||||||||||||||
| Total | $977.89M | $1.02B | $1.30B | $1.52B |
In fiscal 2026, which ended June 30, 2026, the 3 segments Phibro Animal Health Corp reported in this breakdown added up to $1.52B. That was up 17.1% from $1.30B in fiscal 2025. Animal Health was the largest segment, at $1.16B or 76.6% of the total, followed by Mineral Nutrition ($282.34M, 18.6%) and Performance Products ($73.53M, 4.8%). Together, the two largest segments made up 95.2% of this total.
Compared with fiscal 2025, Animal Health grew the fastest, rising 20.7% to $1.16B. Performance Products fell the most, down 8.3% to $73.53M. Over fiscal 2023 to 2026, revenue across these segments went from $977.89M to $1.52B, a compound annual growth rate of 15.8%. Animal Health's share of the total rose from 67.5% to 76.6% over the same years.
The table also keeps 2 segments that Phibro Animal Health Corp no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers 24 fiscal years between 2012 and 2026, as reported in Phibro Animal Health Corp's annual filings.
Phibro Animal Health Corp (PAHC) breaks its revenue down by region, revenue line and segment. In fiscal 2026, its largest region was United States, with $877.13M or 57.8% of the total, followed by Latin America & Canada at $340.67M (22.4%).
United States was Phibro Animal Health Corp's largest region in fiscal 2026, with $877.13M in revenue, 57.8% of the $1.52B reported across its 4 regions.
Mfas & Other was Phibro Animal Health Corp's largest revenue line in fiscal 2026, with $810.73M in revenue, 53.4% of the $1.52B reported across its 5 revenue lines.
Animal Health was Phibro Animal Health Corp's largest segment in fiscal 2026, with $1.16B in revenue, 76.6% of the $1.52B reported across its 3 segments.
Of the Phibro Animal Health Corp regions reported in both fiscal 2025 and fiscal 2026, and making up at least 2% of the total, United States grew the fastest, rising 18.5% from $739.92M to $877.13M.
Every figure is taken from Phibro Animal Health Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2012 to 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.